Bryan Ball Biography and Net Worth

Chief Technical Operations Officer of Whitehawk Therapeutics

Mr. Ball serves as Whitehawk’s Chief Technical Operations Officer, bringing 25 years of experience leading quality, manufacturing and supply chain teams in healthcare-regulated industries. He played a key role in the successful development and approval of the first-in-class TROP2 ADC, Trodelvy, as Chief Quality Officer at Immunomedics. Most recently, Mr. Ball served as the Chief Quality Officer and SVP Operations at Intercept Pharmaceuticals, where he oversaw commercial product and prepared the organization to support regulatory submission of pipeline candidates. Before that, he was at Immunomedics until it was acquired by Gilead Sciences, and previously served as SVP, Global Quality and Safety, Health, and Environmental for Mallinckrodt Pharmaceuticals. Mr. Ball holds an MBA from Westminster College, a Master of Science in Biology from the University of North Carolina and a BS in Biology from Central Michigan University.

What is Bryan Ball's net worth?: The estimated net worth of Bryan Ball is at least $1.58 million as of April 14th, 2026. Mr. Ball owns 397,106 shares of Whitehawk Therapeutics stock worth more than $1,584,453 as of July 22nd. This net worth approximation does not reflect any other investments that Mr. Ball may own. Learn More about Bryan Ball's net worth.
How do I contact Bryan Ball?: The corporate mailing address for Mr. Ball and other Whitehawk Therapeutics executives is 17383 SUNSET AVENUE, SUITE A250, PACIFIC PALISADES, CA, 90272. Whitehawk Therapeutics can also be reached via phone at (424) 473-8055 and via email at [email protected]. Learn More on Bryan Ball's contact information.
Has Bryan Ball been buying or selling shares of Whitehawk Therapeutics?: Bryan Ball has not been actively trading shares of Whitehawk Therapeutics in the last ninety days. Most recently, Bryan Ball sold 92,460 shares of the business's stock in a transaction on Tuesday, April 14th. The shares were sold at an average price of $3.64, for a transaction totalling $336,554.40. Following the completion of the sale, the insider now directly owns 397,106 shares of the company's stock, valued at $1,445,465.84. Learn More on Bryan Ball's trading history.
Who are Whitehawk Therapeutics' active insiders?: Whitehawk Therapeutics' insider roster includes Bryan Ball (Chief Technical Operations Officer), Scott Giacobello (CFO), and David Lennon (President & CEO). Learn More on Whitehawk Therapeutics' active insiders.
Are insiders buying or selling shares of Whitehawk Therapeutics?: During the last year, insiders at the sold shares 14 times. They sold a total of 705,358 shares worth more than $2,584,564.00. The most recent insider tranaction occured on April, 16th when CFO Scott M Giacobello sold 141,600 shares worth more than $584,808.00. Insiders at Whitehawk Therapeutics own 49.9% of the company. Learn More about insider trades at Whitehawk Therapeutics.
Information on this page was last updated on 4/16/2026.

Bryan Ball Insider Trading History at Whitehawk Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/14/2026	Sell	92,460	$3.64	$336,554.40	397,106
4/13/2026	Sell	26,389	$3.46	$91,305.94	489,566
4/10/2026	Sell	6,596	$3.43	$22,624.28	515,955
4/9/2026	Sell	50,000	$3.57	$178,500.00	522,551
3/2/2026	Sell	1,834	$3.31	$6,070.54	206,019

Bryan Ball Buying and Selling Activity at Whitehawk Therapeutics

Whitehawk Therapeutics Company Overview

Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.

Today's Range

Now: $3.99

$3.87

$4.03

50 Day Range

MA: $4.26

$3.79

$5.10

2 Week Range

Now: $3.99

$1.57

$5.49

Volume

473,030 shs

Average Volume

303,038 shs

Market Capitalization

$197.31 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.77